🟢 Nurix Therapeutics is trading 8.45% up in pre-market after reporting $673.1 million in Q3 revenue

Nurix Therapeutics is trading at $24.00, up 8.45% in pre-market after third-quarter results reported October 13.

• Revenue was $673.1 million, including $653.2 million in Roche collaboration license revenue; net income was $549.8 million.
• The Roche deal left Nurix with $1.1 billion in cash and an expected runway into the second half of 2029; bexobrutideg entered Phase 3 development.
• Recent closes near $22 make the pre-market move a notable reversal.